<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501214</url>
  </required_header>
  <id_info>
    <org_study_id>HKUQMHCARE001</org_study_id>
    <nct_id>NCT01501214</nct_id>
  </id_info>
  <brief_title>Use of Atosiban in in Vitro Fertilization (IVF) Treatment</brief_title>
  <official_title>A Randomized Double Blind Comparison of Atosiban in Patients Undergoing in Vitro Fertilization Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vietnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this randomized double blind study is that the live birth rates are
      significantly higher after the use of atosiban prior to the embryo transfer in patients
      undergoing in vitro fertilization (IVF) treatment. This study aims to compare the live birth
      rates of IVF treatment between patients receiving atosiban and placebo prior to the transfer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In-vitro fertilization-embryo transfer (IVF-ET) treatment involves multiple follicular
      development following ovarian stimulation, oocyte retrieval and ET after fertilization.
      Despite recent advances in ovarian stimulation, the method of assisted fertilization and
      improved culture conditions, the implantation potential of embryos remains around 20-25% for
      a long time.

      ET is the final step of an IVF cycle and its success depends on the embryo quality, the
      endometrial receptivity and uterine contractions. Uterine contractions play an important role
      in embryo implantation (Fanchin, 2009) as excessive uterine contractions may expel embryos
      from the uterus and decrease the implantation potential of embryos (Fanchin et al., 1998).

      Ovarian stimulation is used in the great majority of IVF programs so that multiple embryos
      are available for selection and transfer. However, supraphysiological concentrations of
      oestradiol following ovarian stimulation may induce endometrial production of oxytocin,
      formation of oxytocin receptors, and indirectly formation/release of PGF2a (Richter et al.,
      2004; Liedman et al., 2008). It has been shown that uterine contractile activity in IVF
      cycles is increased by approximately 6-fold when measured before ET as compared with the
      situation before ovulation in the natural cycle (Ayoubi et al., 2003). Fanchin et al. (1998)
      have estimated that about 30% of patients undergoing ET have pronounced uterine contractions.
      Uterine contractions can also be triggered after excessive cervical manipulation in difficult
      transfer procedure (Fanchin et al., 1998).

      Drugs to inhibit increased uterine contractions at the time of ET are an attractive approach
      to improve the IVF success. However, the use of beta agonists or non-steroid
      anti-inflammatory drugs has not been shown to provide sufficient benefit (Bernabeu et al.,
      2006; Moon et al., 2004; Tsirigotis et al., 2000). Uterine contractions involve oxytocin and
      therefore inhibition of oxytocin receptors may improve the IVF success by decreasing uterine
      contractions, interfering with PGF2a/oxytocin systems and possibly improving endometrial
      perfusion (Vedernikov et al., 2006).

      Atosiban, a combined oxytocin/vasopressin V1A antagonist, is currently registered for
      clinical use in women suffering from preterm labour. In a multicentre, randomized,
      placebo-controlled trial, it has been shown to reduce the frequency and amplitude of uterine
      contractions in egg donors when compared with placebo (Blockeel et al., 2009; Pierson et al.,
      2009; Visnova et al., 2009). There was a lack of an embryotoxic effect of atosiban in
      concentrations up to 50-fold therapeutic blood concentrations (Pierzynski et al., 2007).
      Atosiban did not affect the survival of 1-cell rabbit embryos, nor decrease the percentage of
      hatched rabbit blastocysts. The human sperm motility bioassay also showed no adverse
      influence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>live birth rate</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>Atosiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atosiban</intervention_name>
    <description>Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.</description>
    <arm_group_label>Atosiban</arm_group_label>
    <other_name>Tractocile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline given</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 43 years

          -  Normal uterine cavity shown on ultrasound scanning

        Exclusion Criteria:

          -  Age &gt;=43

          -  Three previous IVF cycles

          -  Use of donor oocytes

          -  Natural IVF or IVM cycles

          -  Abnormal uterine cavity on ultrasound scanning

          -  ET canceled because of absent fertilization or risk of ovarian hyperstimulation
             syndrome

          -  Blastocyst transfer

          -  Undergoing preimplantation genetic diagnosis

          -  Recruited in the same study before
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest HY Ng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reproductive Medical Center of Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CGRH, School of Medicine</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Ayoubi JM, Epiney M, Brioschi PA, Fanchin R, Chardonnens D, de Ziegler D. Comparison of changes in uterine contraction frequency after ovulation in the menstrual cycle and in in vitro fertilization cycles. Fertil Steril. 2003 May;79(5):1101-5.</citation>
    <PMID>12738502</PMID>
  </reference>
  <reference>
    <citation>Bernabeu R, Roca M, Torres A, Ten J. Indomethacin effect on implantation rates in oocyte recipients. Hum Reprod. 2006 Feb;21(2):364-9. Epub 2005 Nov 10.</citation>
    <PMID>16284067</PMID>
  </reference>
  <reference>
    <citation>Blockeel C, Pierson R, Popovic-Todorovic B, Visnova HA, Garcı´a-Velasco HA, Mra´zek M, Barri PN, Pierzynski P, Kuczynski W, Devroey P, Breinholt V, Erichsen L, Klein BM, Arce JC. Effects of barusiban and atosiban on frequency of uterine contractions in the luteal phase after stimulation: a randomized placebo controlled trial. Hum. Reprod. 24 (Suppl. 1), i26, 2009.</citation>
  </reference>
  <reference>
    <citation>Fanchin R, Ayoubi JM. Uterine dynamics: impact on the human reproduction process. Reprod Biomed Online. 2009;18 Suppl 2:57-62. Review.</citation>
    <PMID>19406033</PMID>
  </reference>
  <reference>
    <citation>Fanchin R, Righini C, Olivennes F, Taylor S, de Ziegler D, Frydman R. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum Reprod. 1998 Jul;13(7):1968-74.</citation>
    <PMID>9740459</PMID>
  </reference>
  <reference>
    <citation>Liedman R, Hansson SR, Howe D, Igidbashian S, McLeod A, Russell RJ, Akerlund M. Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects. Gynecol Endocrinol. 2008 Sep;24(9):508-13. doi: 10.1080/09513590802306218.</citation>
    <PMID>18958771</PMID>
  </reference>
  <reference>
    <citation>Moon HS, Park SH, Lee JO, Kim KS, Joo BS. Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer. Fertil Steril. 2004 Oct;82(4):816-20.</citation>
    <PMID>15482753</PMID>
  </reference>
  <reference>
    <citation>Pierson R, Deptuch JJ, Invik J, Klein BM, Breinholt V, Arce JC. Reproducibility of uterine contractility assessments based on transvaginal ultrasound cine-loop recordings. Hum. Reprod. 24 (Suppl. 1), i103, 2009.</citation>
  </reference>
  <reference>
    <citation>Pierzynski P, Gajda B, Smorag Z, Rasmussen AD, Kuczynski W. Effect of atosiban on rabbit embryo development and human sperm motility. Fertil Steril. 2007 May;87(5):1147-52. Epub 2007 Jan 16.</citation>
    <PMID>17224148</PMID>
  </reference>
  <reference>
    <citation>Richter ON, Kübler K, Schmolling J, Kupka M, Reinsberg J, Ulrich U, van der Ven H, Wardelmann E, van der Ven K. Oxytocin receptor gene expression of estrogen-stimulated human myometrium in extracorporeally perfused non-pregnant uteri. Mol Hum Reprod. 2004 May;10(5):339-46. Epub 2004 Mar 25.</citation>
    <PMID>15044599</PMID>
  </reference>
  <reference>
    <citation>Tsirigotis M, Pelekanos M, Gilhespie S, Gregorakis S, Pistofidis G. Ritodrine use during the peri-implantation period reduces uterine contractility and improves implantation and pregnancy rates post-ivf. Hum. Reprod. 15, (Abs. Bk 1), O-024, 10, 2000.</citation>
  </reference>
  <reference>
    <citation>Vedernikov Y, Betancourt A, Shi S, Shi L, Reinheimer T, Garfield R. (2006) Oxytocin antagonistic effect of barusiban and atosiban in isolated uterine artery from late pregnant rats. In: Annual scientific meeting of the Society for Gynecologic Investigation. Toronto, Canada.</citation>
  </reference>
  <reference>
    <citation>Visnova H, Coroleu B, Piro M, Blockeel C, Mrazek M, Arce JC. Barusiban and atosiban for reduction of uterine contractions on day of embryo transfer do not alter the endocrine profile at time of implantation. Hum. Reprod. 24 (Suppl. 1), i178, 2009.</citation>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2011</study_first_submitted>
  <study_first_submitted_qc>December 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atosiban</keyword>
  <keyword>in vitro fertilization</keyword>
  <keyword>subfertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atosiban</mesh_term>
    <mesh_term>Vasotocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

